BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kozlowski P, Kameran Behnam K, Uggla B, Åström M. Carfilzomib-induced hemolysis is noticeably common but rarely shows features of thrombotic microangiopathy: A retrospective study. Eur J Haematol 2020;104:588-93. [PMID: 32115785 DOI: 10.1111/ejh.13401] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Thomas MR, Scully M. How I treat microangiopathic hemolytic anemia in patients with cancer. Blood 2021;137:1310-7. [PMID: 33512445 DOI: 10.1182/blood.2019003810] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
2 Kozlowski P, Kameran Behnam K, Uggla B, Åström M. Carfilzomib-induced hemolysis is noticeably common but rarely shows features of thrombotic microangiopathy: A retrospective study. Eur J Haematol 2020;104:588-93. [PMID: 32115785 DOI: 10.1111/ejh.13401] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Freyer CW, Bange EM, Skuli S, Hsu M, Lin J, Cuker A, Cohen AD, Garfall A. Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome in a Patient With Heterozygous CFHR3/CFHR1 Deletion Treated With Eculizumab. Clin Lymphoma Myeloma Leuk 2021:S2152-2650(21)00248-2. [PMID: 34366267 DOI: 10.1016/j.clml.2021.06.019] [Reference Citation Analysis]